1999 Fiscal Year Final Research Report Summary

Expression of the SART-1 tumor rejection antigen in Breast

Research Project

Project/Area Number	10671143
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Single-year Grants
Section	一般
Research Field	General surgery
Research Institution	Kurume University
Principal Investigator	KOGA Toshihiro KURUME Univ., Sch. Med., Lecturer, 医学部, 講師 (40186648)
Co-Investigator(Kenkyū-buntansha)	SHICHIJO Shigeki KURUME Univ., Sch. Med., Assistant Professor, 医学部, 助教授 (30080592) KAWAMOTO Mayumi KURUME Univ., Sch. Med., Assistant, 医学部, 助手 (40289377)
Project Period (FY)	1998 – 1999
Keywords	breast cancer / SART-1
Research Abstract	We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-l antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell line tested, but not in normal breast tissues. The SART-1 breast cancer cells transfected with HLA-A2601 or HLA-A2402 cDNA were recognized by the HLA-A26-restricted and SART-1 specific cytotoxic T lymphocytes (CTLs) or the HLA-A24-restricted and SART-1-speciflC CTLs, respectively. Among the 20 SART-1 tumors, 9 or 8 tumors expressed estrogen receptor or progesterone receptor, respectively. Therefore, the patients with HLA-A26 or -A24 haplotype might be appropriate candidates for specific immunotherapy with the SART-1 peptides independently or in combination with hormone therapy.

(2 results)